A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
Status:
Completed
Trial end date:
2019-01-24
Target enrollment:
Participant gender:
Summary
The current study is designed to demonstrate the non-inferiority of CJ-12420-based triple
therapy (CJ-12420, amoxicillin and clarithromycin) versus lansoprazole-based triple therapy
(lansoprazole, amoxicillin and clarithromycin) in H. pylori eradication rate and to evaluate
the safety of CJ-12420 following oral administration of either triple therapy twice daily for
7 days in H. pylori positive patients.